Pay in installments of $30.00 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
CD27 Fc Chimera Protein, MouseProduct Specification Species Mouse Synonyms TNFRSF7, T14, S152, Tp55, Cluster of differentiation 27 Accession P41272 Amino Acid Sequence Thr21 Arg182 with Human IgG1 Fc at the C Terminus Expression System HEK293 Molecular Weight 50 70kDa (Reducing) Purity >95% by SDS PAGE, RP HPLC&SEC HPLC Endotoxin <0. 1EU g Conjugation Unconjugated Tag Human IgG1 Fc Physical Appearance Lyophilized Powder Storage Buffer PBS, pH7. 4, 5% trehalose Reconstitution
Product Specification
| Species | Mouse |
| Synonyms | TNFRSF7, T14, S152, Tp55, Cluster of differentiation 27 |
| Accession | P41272 |
| Amino Acid Sequence | Thr21-Arg182 with Human IgG1 Fc at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 50-70kDa (Reducing) |
| Purity | >95% by SDS-PAGE, RP-HPLC&SEC-HPLC |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | Human IgG1 Fc |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference |
|
Background
Cluster of Differentiation 27 (CD27) is a member of the Tumor Necrosis Factor Receptor superfamily and is integral to T-cell activation, providing a crucial costimulatory signal. When CD27 binds to its natural ligand, CD70, it enhances T-cell proliferation and the differentiation of effector and memory T cells. This interaction holds potential as an immune modulatory target for cancer treatment.
The CD27 agonistic antibody, varlilumab, has demonstrated promising efficacy in both hematological malignancies and solid tumors. Current research is focused on studying the combination therapy of varlilumab with PD-1 axis inhibitors, such as nivolumab or atezolizumab, which target immune checkpoint pathways.
Furthermore, CD70 expression is being explored as a therapeutic target for Antibody-Drug Conjugates (ADCs), antibodies that induce Antibody-Dependent Cellular Cytotoxicity (ADCC), as well as for chimeric antigen receptor (CAR) gene-modified T cells and specific dendritic cell vaccinations.
Clinical trials have shown that targeting the CD27 axis is feasible and safe, with the most common side effects being thrombocytopenia, fatigue, and nausea.
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy